An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
about
Prediction of cancer drugs by chemical-chemical interactionsSunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancerThe three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.Minireview: Basal-like breast cancer: from molecular profiles to targeted therapiesPrediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.Targeting angiogenesis in metastatic breast cancerSunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.Current and emerging targeted therapies for metastatic breast cancer.Pazopanib for the treatment of breast cancer.Antiangiogenic therapy in the management of breast cancer.Drug interactions with sunitinib.Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumoursPharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor.Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
P2860
Q28539449-9EF773FA-D3C0-48C0-8A20-F04731040E98Q33409913-D1DAAD7F-0839-4DAE-B938-126365037107Q33413742-6109CBE6-8445-471B-8C7C-970139B4DB75Q33739313-3F62B0F5-5264-4EE7-A55A-54C7D01B1508Q33903662-0BC47545-63DD-4896-8287-ED62F5D5B041Q34562257-5F9968BC-2E83-47E8-B7BE-075FA1D3AC29Q35115436-125BF5BA-4655-43EA-A5F0-4906DC70170EQ35583942-77E6F3F8-5DEF-403D-866F-81B14022C6D5Q36182795-F034F3CF-DEB7-41B2-A175-6C1CCB715EF0Q36197026-830BAEB3-EC89-4606-8D5C-A5023013CF2BQ37707145-1E26F2D3-531C-4FAF-A2B5-CDB4471B6A44Q37946797-C8202FD2-57F0-47A0-A5B1-4C4A2EB94DD0Q37974693-C576D182-180B-4D7B-8C64-4D94DAF73F29Q38035101-ABF2CDA6-A39A-463B-BE3B-60E64006FBC9Q38176853-C031D645-8DDA-48B3-A225-D8DF2D34C119Q38193533-B53564B2-D5A9-4846-81B4-254833D3D219Q38285656-874ED53D-3EC0-433C-A733-CE3A8AE1FCE4Q38552109-72483EB2-61BE-4D6E-B2D6-D1ED86C4F90DQ43841175-5601717A-FE36-40F4-97A6-96874729BCACQ47410775-E6D51524-20D1-4A4E-BACD-478FA14FFE62Q47957959-15B839E3-6B03-4C3C-9DCF-85E272DA29D2
P2860
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
An exploratory study of suniti ...... s with advanced breast cancer.
@ast
An exploratory study of suniti ...... s with advanced breast cancer.
@en
type
label
An exploratory study of suniti ...... s with advanced breast cancer.
@ast
An exploratory study of suniti ...... s with advanced breast cancer.
@en
prefLabel
An exploratory study of suniti ...... s with advanced breast cancer.
@ast
An exploratory study of suniti ...... s with advanced breast cancer.
@en
P2093
P2860
P356
P1433
P1476
An exploratory study of suniti ...... s with advanced breast cancer.
@en
P2093
P A Gowland
P E Cataruozolo
P2860
P304
P356
10.1093/ANNONC/MDP565
P577
2009-12-23T00:00:00Z